JPWO2022223969A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022223969A5 JPWO2022223969A5 JP2023564219A JP2023564219A JPWO2022223969A5 JP WO2022223969 A5 JPWO2022223969 A5 JP WO2022223969A5 JP 2023564219 A JP2023564219 A JP 2023564219A JP 2023564219 A JP2023564219 A JP 2023564219A JP WO2022223969 A5 JPWO2022223969 A5 JP WO2022223969A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- referred
- binding complex
- peptide ligand
- multimeric binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 70
- 239000003446 ligand Substances 0.000 claims description 57
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 13
- 229940079593 drug Drugs 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 229920001184 polypeptide Polymers 0.000 claims description 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 12
- 239000002062 molecular scaffold Substances 0.000 claims description 10
- 102000008212 P-Selectin Human genes 0.000 claims description 9
- 108010035766 P-Selectin Proteins 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 208000035475 disorder Diseases 0.000 claims description 8
- 235000001014 amino acid Nutrition 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 102000016289 Cell Adhesion Molecules Human genes 0.000 claims description 4
- 108010067225 Cell Adhesion Molecules Proteins 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 208000007056 sickle cell anemia Diseases 0.000 claims description 4
- 125000006850 spacer group Chemical group 0.000 claims description 4
- 230000001629 suppression Effects 0.000 claims description 4
- 239000012636 effector Substances 0.000 claims description 3
- 125000000524 functional group Chemical group 0.000 claims description 3
- IYKLZBIWFXPUCS-VIFPVBQESA-N (2s)-2-(naphthalen-1-ylamino)propanoic acid Chemical compound C1=CC=C2C(N[C@@H](C)C(O)=O)=CC=CC2=C1 IYKLZBIWFXPUCS-VIFPVBQESA-N 0.000 claims description 2
- -1 1,1',1''-(1,4,7-triazonane-1,4,7-triyl)tris(2-bromoethan- 1 -one) Chemical compound 0.000 claims description 2
- FYBFGAFWCBMEDG-UHFFFAOYSA-N 1-[3,5-di(prop-2-enoyl)-1,3,5-triazinan-1-yl]prop-2-en-1-one Chemical compound C=CC(=O)N1CN(C(=O)C=C)CN(C(=O)C=C)C1 FYBFGAFWCBMEDG-UHFFFAOYSA-N 0.000 claims description 2
- VITRFBWOHICMMS-UHFFFAOYSA-N 1-[4,7-bis(2-chloroacetyl)-1,4,7-triazonan-1-yl]-2-chloroethanone Chemical compound ClCC(=O)N1CCN(C(=O)CCl)CCN(C(=O)CCl)CC1 VITRFBWOHICMMS-UHFFFAOYSA-N 0.000 claims description 2
- PVFOHMXILQEIHX-UHFFFAOYSA-N 8-[(6-bromo-1,3-benzodioxol-5-yl)sulfanyl]-9-[2-(2-bromophenyl)ethyl]purin-6-amine Chemical compound C=1C=2OCOC=2C=C(Br)C=1SC1=NC=2C(N)=NC=NC=2N1CCC1=CC=CC=C1Br PVFOHMXILQEIHX-UHFFFAOYSA-N 0.000 claims description 2
- 208000025721 COVID-19 Diseases 0.000 claims description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 206010027476 Metastases Diseases 0.000 claims description 2
- CZCIKBSVHDNIDH-NSHDSACASA-N N(alpha)-methyl-L-tryptophan Chemical compound C1=CC=C2C(C[C@H]([NH2+]C)C([O-])=O)=CNC2=C1 CZCIKBSVHDNIDH-NSHDSACASA-N 0.000 claims description 2
- CZCIKBSVHDNIDH-UHFFFAOYSA-N Nalpha-methyl-DL-tryptophan Natural products C1=CC=C2C(CC(NC)C(O)=O)=CNC2=C1 CZCIKBSVHDNIDH-UHFFFAOYSA-N 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- 206010040642 Sickle cell anaemia with crisis Diseases 0.000 claims description 2
- 150000003863 ammonium salts Chemical class 0.000 claims description 2
- 125000002619 bicyclic group Chemical group 0.000 claims description 2
- 230000000903 blocking effect Effects 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 230000009401 metastasis Effects 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229950004730 crizanlizumab Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000023404 leukocyte cell-cell adhesion Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163177185P | 2021-04-20 | 2021-04-20 | |
| US63/177,185 | 2021-04-20 | ||
| PCT/GB2022/050995 WO2022223969A1 (en) | 2021-04-20 | 2022-04-20 | Bicyclic peptide ligands specific for p-selectin |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024515306A JP2024515306A (ja) | 2024-04-08 |
| JP2024515306A5 JP2024515306A5 (https=) | 2025-04-28 |
| JPWO2022223969A5 true JPWO2022223969A5 (https=) | 2025-04-28 |
Family
ID=81448343
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023564219A Pending JP2024515306A (ja) | 2021-04-20 | 2022-04-20 | Ｐ－セレクチンに特異的な二環式ペプチドリガンド |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US12150998B2 (https=) |
| EP (1) | EP4326743A1 (https=) |
| JP (1) | JP2024515306A (https=) |
| CN (1) | CN117203219A (https=) |
| WO (1) | WO2022223969A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201918557D0 (en) * | 2019-12-16 | 2020-01-29 | Bicycle Tx Ltd | Bicyclic peptide ligands specific for IL-17 |
| CN117203219A (zh) | 2021-04-20 | 2023-12-08 | 拜斯科技术开发有限公司 | 特异性针对p-选择素的双环肽配体 |
| WO2025168211A1 (en) | 2023-02-10 | 2025-08-14 | Novo Nordisk A/S | P-selectin peptide ligands |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1288222A1 (en) | 2001-09-03 | 2003-03-05 | Yamanouchi Europe B.V. | Peptidic compounds selectively binding to P-selectin |
| EP1481683A1 (en) | 2003-05-30 | 2004-12-01 | Yamanouchi Pharmaceutical Co. Ltd. | P-selectin targeting ligand and compositions thereof |
| AU2009211253B2 (en) | 2008-02-05 | 2014-11-06 | Bicyclerd Limited | Methods and compositions |
| CA2966642C (en) * | 2014-11-07 | 2023-03-28 | Northwestern University | Ornithine aminotransferase inhibition with gaba analogues for treatment of hepatocellular carcinoma |
| GB201706477D0 (en) * | 2017-04-24 | 2017-06-07 | Bicycle Therapeutics Ltd | Modification of polypeptides |
| WO2018197893A1 (en) | 2017-04-27 | 2018-11-01 | Bicycletx Limited | Bicyclic peptide ligands and uses thereof |
| JP2021514953A (ja) * | 2018-02-23 | 2021-06-17 | バイスクルテクス・リミテッド | 多量体二環式ペプチドリガンド |
| WO2020084305A1 (en) * | 2018-10-23 | 2020-04-30 | Bicycletx Limited | Bicyclic peptide ligands and uses thereof |
| CN117203219A (zh) | 2021-04-20 | 2023-12-08 | 拜斯科技术开发有限公司 | 特异性针对p-选择素的双环肽配体 |
-
2022
- 2022-04-20 CN CN202280029420.5A patent/CN117203219A/zh active Pending
- 2022-04-20 EP EP22720008.6A patent/EP4326743A1/en not_active Withdrawn
- 2022-04-20 US US17/659,934 patent/US12150998B2/en active Active
- 2022-04-20 WO PCT/GB2022/050995 patent/WO2022223969A1/en not_active Ceased
- 2022-04-20 JP JP2023564219A patent/JP2024515306A/ja active Pending
-
2024
- 2024-10-21 US US18/921,910 patent/US20250064950A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024062998A5 (https=) | ||
| EP3062823B1 (en) | Novel polypeptides | |
| Ricklin | Manipulating the mediator: modulation of the alternative complement pathway C3 convertase in health, disease and therapy | |
| US7718610B2 (en) | Retrocyclins: antiviral and antimicrobial peptides | |
| JPWO2021019243A5 (https=) | ||
| JPWO2021019244A5 (https=) | ||
| JPWO2020120980A5 (https=) | ||
| JPWO2020148525A5 (https=) | ||
| JPWO2020148528A5 (https=) | ||
| WO1991018010A1 (en) | Inhibition of viral infection using intercellular adhesion molecule-1-like peptides and/or analogues thereof | |
| JPWO2020148526A5 (https=) | ||
| JPWO2020128527A5 (https=) | ||
| Döring et al. | Identification and characterization of a TNFα antagonist derived from a monoclonal antibody | |
| JPWO2020148527A5 (https=) | ||
| JPWO2020230780A5 (https=) | ||
| JP2024515306A (ja) | Ｐ－セレクチンに特異的な二環式ペプチドリガンド | |
| JPWO2022223969A5 (https=) | ||
| JPWO2020148529A5 (https=) | ||
| JPWO2020120981A5 (https=) | ||
| JPWO2020120983A5 (https=) | ||
| Hui et al. | Design of rat renin inhibitory peptides | |
| WO2004033479A2 (en) | Retroyclins: antiviral and antimicrobial peptides | |
| EP1389126A1 (en) | Retrocyclins: antiviral and antimicrobial peptides | |
| JPWO2020120978A5 (https=) | ||
| JP2024504074A (ja) | 抗感染性二環式ペプチドリガンド |